Manhattan Scientifics, Inc. (OTCQB:MHTX) has recruited Robert R. Proulx
(pronounced “Pru”) to the position of President and Chief Operating
Officer of its Senior Scientific LLC subsidiary, effective January 12.
As previously announced, Gerald Grafe, former president of Senior
Scientific, is remaining with Senior Scientific to focus on strategic
relationships and intellectual property issues. Edward R. Flynn, PhD,
founder of Senior Scientific, is remaining as Chief Scientist.
Mr. Proulx’s responsibilities will include building Senior Scientific’s
core capabilities in nano-particle technology and expanding on the
collaborations in place with the MD Anderson Cancer Center in Houston
and The University of New Mexico Health Sciences Center, Albuquerque, to
help further develop and strategically position Senior Scientific’s MRX
diagnostic technology for the non-invasive early detection of cancer.
Mr. Proulx, age 57, is a veteran business executive with more than 25
years of leadership experience for both private and public companies in
the life science and diagnostic device markets. Most recently, he served
as Chief Commercial Officer and General Manager of U.S. Operations for
Silicon Biosystems, Inc., whose image-based cell sorting technology is
advancing personalized medicine initiatives in cancer through the
molecular characterization of tumor heterogeneity. Earlier, he served as
Vice President, Marketing & Sales at Nanogen, Inc., where he was
responsible for worldwide corporate branding, product marketing and
North American sales operations for the company’s in vitro diagnostic
products. Prior to this, he held senior-level positions at Gene Logic
Inc.; IGEN International, Inc.; Packard Instrument Company, Inc. and
Bio-Tek Instruments, Inc. He has served on the board of directors of
Semrock and PGXL Diagnostic Laboratories and has been a volunteer in the
CONNECT Springboard Entrepreneurs in Residence program, helping nurture
startups through early-stage business planning. His bachelor’s and
master’s degrees are from The State University of New York at Albany and
he is a graduate of the Executive Management Program at The Pennsylvania
State University Smeal College of Business.
Mr. Proulx said, “With more than two and a half decades in the life
science arena, I have helped bring to market a fair number of
cutting-edge technologies. I am convinced that Senior Scientific’s MRX
diagnostic technology represents a bold new step in cancer care, and I
look forward to working with the rest of the management team as we
continue to develop the technology and pursue the path to
commercialization.”
Manny Tsoupanarias, CEO of Manhattan Scientifics, said, “Bob Proulx
brings a tremendous amount of industry experience to Senior Scientific,
and we are fortunate to have him serve as its new President and COO. We
will undoubtedly benefit from his keen insights as we expand the
development of our MRX diagnostic technology and enter the
commercialization stage. At the same time, we are grateful for Gerald
Grafe’s dedication as President and are gratified he will remain with
Senior Scientific to guide our strategy and IP issues, while also
ensuring a smooth transition in leadership.”
About Manhattan Scientifics, Inc.
Manhattan Scientifics Inc. is located in New Mexico, New York and
Montreal, is focused on the commercialization of disruptive technologies
in the nano-medicine space. It has achieved several critical milestones
in the development of its proprietary technology for the very early
detection of cancer. The company is also at work with its licensed NYSE
"partner" to commercialize medical prosthetics applications for its
patented ultra-fine-grain nanotechnology metals.
About Senior Scientific LLC
Senior Scientific, LLC (www.seniorscientific.com)
is a New Mexico Company with research facilities located at the
University of New Mexico Science and Technology Park in Albuquerque, New
Mexico and longstanding relationships with the University of New Mexico
Health Sciences Center, the Los Alamos National Laboratories, and the
Center for Integrated Nanotechnology (CINT) at Sandia National
Laboratory. The Company’s focus is in the emerging field of molecular
imaging and nanobiotechnology for the early detection and localization
of cancer and other human diseases, and is the leader in a technology
called Nanomagnetic Relaxometry. Its proprietary technologies and
methods employ magnetic nanoparticles targeted towards cells associated
with cancer and other diseases, and detect those cells tagged with
magnetic nanoparticles through sophisticated magnetic sensors.
Forward-looking statement
This press release contains forward-looking statements, which are
subject to a number of risks, assumptions and uncertainties that could
cause the Company's actual results to differ materially from those
projected in such forward-looking statements. Management at Manhattan
Scientifics believes that purchase of its shares should be considered to
be at the high end of the risk spectrum. Forward-looking statements
speak only as of the date made and are not guarantees of future
performance. We undertake no obligation to publicly update or revise any
forward-looking statements.
Copyright Business Wire 2015